Phreesia, Inc. (PHR) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $10.30 (-0.39%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 4, 2026 | Steven Valiquette | Mizuho Securities | $22.00 | +113.5% |
| Jan 8, 2026 | Stan Berenshteyn | Wells Fargo | $30.00 | +191.1% |
| Dec 10, 2025 | Steven Valiquette | Mizuho Securities | $28.00 | +171.7% |
| Dec 9, 2025 | Richard Close | Canaccord Genuity | $33.00 | +220.2% |
| Dec 2, 2025 | Clark Wright | D.A. Davidson | $35.00 | +239.6% |
| Sep 8, 2025 | Aaron Kimson | JMP Securities | $34.00 | +229.9% |
| Sep 5, 2025 | Richard Close | Canaccord Genuity | $38.00 | +268.8% |
| Dec 11, 2024 | Joe Vruwink | Robert W. Baird | $30.00 | +191.1% |
| Nov 29, 2024 | Gil Luria | D.A. Davidson | $32.00 | +210.5% |
| Sep 6, 2024 | Jailendra Singh | Truist Financial | $31.00 | +200.8% |
| Sep 6, 2024 | Joe Vruwink | Robert W. Baird | $34.00 | +229.9% |
| Sep 5, 2024 | Sean Wieland | Piper Sandler | $30.00 | +191.1% |
| May 31, 2024 | Richard Close | Canaccord Genuity | $34.00 | +229.9% |
| May 29, 2024 | Jailendra Singh | Truist Financial | $35.00 | +239.6% |
| May 24, 2024 | Scott Schoenhaus | KeyBanc | $30.00 | +191.1% |
| Mar 21, 2024 | Aaron Kimson | JMP Securities | $30.00 | +191.1% |
| Mar 18, 2024 | Joe Vruwink | Robert W. Baird | $31.00 | +200.8% |
| Mar 15, 2024 | Sean Dodge | RBC Capital | $23.00 | +123.2% |
| Dec 6, 2023 | Ryan MacDonald | Needham | $29.00 | +181.4% |
| Sep 7, 2023 | Jeff Garro | Stephens | $37.00 | +259.0% |
Top Analysts Covering PHR
PHR vs Sector & Market
| Metric | PHR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.44 | 2.25 | 2.42 |
| Analyst Count | 27 | 8 | 18 |
| Target Upside | +16.9% | +16187.2% | +19.5% |
| P/E Ratio | 69.31 | 3.72 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-10-31 | $136M | $139M | $144M | 5 |
| 2027-01-31 | $505M | $516M | $545M | 14 |
| 2027-04-30 | $135M | $137M | $140M | 6 |
| 2027-07-31 | $134M | $136M | $139M | 7 |
| 2027-10-31 | $134M | $136M | $139M | 7 |
| 2028-01-31 | $134M | $136M | $139M | 10 |
| 2028-04-30 | $141M | $143M | $146M | 9 |
| 2028-07-31 | $140M | $142M | $145M | 10 |
| 2028-10-31 | $141M | $142M | $146M | 10 |
| 2029-01-31 | $141M | $143M | $146M | 6 |
| 2030-01-31 | $525M | $539M | $553M | 2 |
| 2031-01-31 | $538M | $552M | $567M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-10-31 | $0.15 | $0.16 | $0.17 | 2 |
| 2027-01-31 | $0.18 | $0.32 | $0.69 | 9 |
| 2027-04-30 | $0.20 | $0.20 | $0.20 | 4 |
| 2027-07-31 | $0.21 | $0.21 | $0.22 | 4 |
| 2027-10-31 | $0.22 | $0.22 | $0.23 | 3 |
| 2028-01-31 | $0.22 | $0.22 | $0.23 | 4 |
| 2028-04-30 | $0.00 | $0.00 | $0.00 | 3 |
| 2028-07-31 | $0.00 | $0.00 | $0.00 | 3 |
| 2028-10-31 | $0.00 | $0.00 | $0.00 | 3 |
| 2029-01-31 | $0.00 | $0.00 | $0.00 | 2 |
| 2030-01-31 | $0.85 | $0.88 | $0.91 | 2 |
| 2031-01-31 | $0.91 | $0.94 | $0.97 | 3 |
Frequently Asked Questions
What is the analyst consensus for PHR?
The consensus among 27 analysts covering Phreesia, Inc. (PHR) is Buy with an average price target of $13.57.
What is the highest price target for PHR?
The highest price target for PHR is $73.00, set by Donald Hooker at KeyBanc on 2021-07-12.
What is the lowest price target for PHR?
The lowest price target for PHR is $22.00, set by Steven Valiquette at Mizuho Securities on 2026-02-04.
How many analysts cover PHR?
27 analysts have issued ratings for Phreesia, Inc. in the past 12 months.
Is PHR a buy or sell right now?
Based on 27 analyst ratings, PHR has a consensus rating of Buy (2.44/5) with a +16.9% upside to the consensus target of $13.57.
What are the earnings estimates for PHR?
Analysts estimate PHR will report EPS of $0.16 for the period ending 2026-10-31, with revenue estimated at $139M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.